Leif Niclas Fredrik Löwgren
Director/Board Member bei Omnivation AB
Profil
Leif Niclas Fredrik Löwgren is currently a Director at Omnivation AB.
He was previously a Director at Copperstone Resources AB, QuiaPEG Pharmaceuticals AB, NextCell Pharma AB, and Quiapeg Pharmaceuticals Holding AB.
Mr. Löwgren holds an MBA from the University of Stockholm.
Aktive Positionen von Leif Niclas Fredrik Löwgren
Unternehmen | Position | Beginn |
---|---|---|
Omnivation AB | Director/Board Member | - |
Ehemalige bekannte Positionen von Leif Niclas Fredrik Löwgren
Unternehmen | Position | Ende |
---|---|---|
COPPERSTONE RESOURCES AB | Director/Board Member | 14.05.2019 |
NEXTCELL PHARMA AB | Director/Board Member | - |
QUIAPEG PHARMACEUTICALS HOLDING AB | Director/Board Member | - |
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Director/Board Member | - |
Ausbildung von Leif Niclas Fredrik Löwgren
University of Stockholm | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
COPPERSTONE RESOURCES AB | Non-Energy Minerals |
NEXTCELL PHARMA AB | Health Technology |
QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
Private Unternehmen | 2 |
---|---|
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Health Technology |
Omnivation AB |